BRIEF-Bayer Phase III Prostate Cancer Trial Cuts Metastasis Or Death Risk 58%

2

Oct 24 (Reuters) – BAYER AG: * PHASE III DASL-HICAP TRIAL MET PRIMARY ENDPOINT OF METASTASIS-FREE SURVIVAL * DAROLUTAMIDE PLUS ADT AND RADIATION THERAPY REDUCED RISK OF METASTASIS OR DEATH BY 58% IN

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)